Baron Health Care Fund Q1 2026 Shareholder Letter
The Baron Health Care Fund reported a decline in Q1 2026, underperforming its benchmark, the Russell 3000 Health Care Index. Since its inception, the fund has achieved an annualized return of 9.39%, slightly outperforming the benchmark's 8.97% gain. Key contributors to the fund's performance included Arcellx, Inc., Roivant Sciences Ltd., and AstraZeneca PLC, while detractors included Eli Lilly and Company, Thermo Fisher Scientific Inc., and RadNet.
- ▪The Baron Health Care Fund declined in Q1 2026.
- ▪It underperformed the Russell 3000 Health Care Index.
- ▪Since inception, the fund has increased 9.39% annually compared to the benchmark's 8.97% gain.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":{"id":"DoxFkP"},"item":"https://seekingalpha.com/latest-articles"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909322-baron-health-care-fund-q1-2026-shareholder-letter"},"author":{"@type":"Person","name":"Baron Capital","url":"https://seekingalpha.com/author/baron-capital"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
